363 related articles for article (PubMed ID: 37298276)
21. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
23. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
24. Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.
Yuan X; Gao Z; Hao Z; Ma H; Duan K; Yang C
Medicine (Baltimore); 2023 Oct; 102(43):e35739. PubMed ID: 37904378
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
28. Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.
Yuan X; Gao Z; Yang C; Duan K; Ren L; Song G
Front Endocrinol (Lausanne); 2023; 14():1170881. PubMed ID: 37342259
[TBL] [Abstract][Full Text] [Related]
29. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
Ard J; Fitch A; Fruh S; Herman L
Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.
Makri E; Kita M; Goulas A; Papaioannidou P; Efstathiadou ZA; Adamidou F; Polyzos SA
Diabetes Metab Syndr; 2020; 14(6):1913-1919. PubMed ID: 33011499
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
[TBL] [Abstract][Full Text] [Related]
32. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Dougherty JA; Guirguis E; Thornby KA
Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
[TBL] [Abstract][Full Text] [Related]
33. [A new era for glucagon-like peptide-1 receptor agonists].
Neuville MF; Paquot N; Scheen AJ
Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
[TBL] [Abstract][Full Text] [Related]
34. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.
Xie W; Hong Z; Li B; Huang B; Dong S; Cai Y; Ruan L; Xu Q; Mou L; Zhang Y
J Diabetes Complications; 2024 Jun; 38(6):108743. PubMed ID: 38688179
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
Dai Y; He H; Li S; Yang L; Wang X; Liu Z; An Z
Front Endocrinol (Lausanne); 2020; 11():622589. PubMed ID: 33664710
[TBL] [Abstract][Full Text] [Related]
36. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
Liu Y; Wei R; Hong TP
World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
[TBL] [Abstract][Full Text] [Related]
37. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
[TBL] [Abstract][Full Text] [Related]
38. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1.
Yin YH; Sang LX; Chang B
World J Gastroenterol; 2023 Dec; 29(48):6235-6238. PubMed ID: 38186863
[TBL] [Abstract][Full Text] [Related]
39. Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.
Gracen L; Muthukumara W; Aikebuse M; Russell A; O'Beirne J; Irvine KM; Williams S; Puri G; Valery PC; Hayward KL; Powell EE
Ann Hepatol; 2023; 28(6):101142. PubMed ID: 37468097
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Nauck MA; Mirna AEA; Quast DR
Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
